You searched for Antibody candidate - Page 16 of 69

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

…core focus is the discovery and development of new antibody-based drugs for the treatment of cancer, immune disorders, and inflammatory diseases. Novimmune’s innovation lies in their monoclonal and bispecific antibody…

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

inflarx inflammation fundraising itx 1 biotech antibody

News and Trends 22 Jul 2016

German Biotech raises extra €31M to get first-in-class Antibody through trials

InflaRx, a German-based biopharma, has raised €31M in a series C fundraising. This is to further advance a potentially first-in-class antibody which targets an acute form of self-inflammation. Based in…

July 22, 2016 - 2 minutesmins - By Dani Bancroft

covid 19 vaccines adenovirus adenoviral vector

News and Trends 8 Jun 2022

New COVID antibody cocktail developed

…in live virus neutralization assays. The cocktail and each antibody also outperformed other monoclonal treatments currently approved or authorized by the FDA and EMA, particularly against Omicron. “Antibody cocktails will…

June 8, 2022 - 2 minutesmins - By Jim Cornall

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

…antibody libraries in the industry. The antibody specialist may therefore receive up to €710 million in various payments, with a non-refundable €25M also being offered as an upfront fee. The…

July 13, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

…of Health, US. ViiV Healthcare’s majority shareholder, the pharma company GSK, licensed the antibody from the US organization, and ViiV Healthcare will launch a phase IIa trial of the antibody…

November 22, 2019 - 2 minutesmins - By Jonathan Smith

llama leo pharma argen x skin milestone inflammatory

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

…many skin conditions. An example of the SIMPLE Antibody range includes arGEN-X’s candidate ARGX-110, which depletes the small subset of CD70 positive B- and T-cells, as a therapeutic angle of…

February 3, 2016 - 2 minutesmins - By Dani Bancroft

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

…Phase Ib trial assessing the safety and tolerability of Genentech’s candidate, DSTA4637S, which combines Symphogen’s antibody with an antibiotic agent. Staphylococcus aureus infections are particularly deadly, with an annual incidence…

November 30, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Feb 2017

In the Age of Biological Therapeutics, Chemists move to ADCs

…ADCs include the absence of data on unconjugated antibody testing, criteria for an acceptable amount of unconjugated antibody, and data relating to the drug-antibody ratio. Images from the author …

February 23, 2017 - 4 minutesmins - By Evelyn Warner

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

…a monoclonal antibody – which binds to the cancer protein in a cell – attached to a linker, which delivers the anticancer drug once the antibody latches on to the…

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work…

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

CureVac: From a failed mRNA-based COVID-19 vaccine to a €400 million deal with GSK

In Depth 1 Aug 2024

CureVac: From a failed drug to a €1.45 billion deal

…the race with its first-generation COVID-19 vaccine, CVnCoV, it did not come first, and didn’t even finish the race. Indeed, CureVac faced significant setbacks with its COVID candidates, allowing Moderna…

August 1, 2024 - 8 minutesmins - By Jules Adam

organoids in a dish, drug development, patient relevant model

The organoid era: bringing patient-relevant preclinical models to the lab

…in a large patient sample.” This led to the identification of a promising candidate. “An extended screen with CRC organoid models showed that the newly identified antibody effectively blocked tumor…

July 12, 2022 - 7 minutesmins - By Sudha Sundaram

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

German Biotech raises extra €31M to get first-in-class Antibody through trials

New COVID antibody cocktail developed

French Pharma licenses California PD-1 Cancer Antibody for €710M

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

In the Age of Biological Therapeutics, Chemists move to ADCs

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

CureVac: From a failed drug to a €1.45 billion deal

The organoid era: bringing patient-relevant preclinical models to the lab

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!